Pharmafile Logo
Pharmafocus logo
Advanced Search

Genentech

Showing 15 posts of 91 posts found.

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024
Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …

News

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023
Research and Development Genentech, Oncology, breast cancer, oncology

Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …

News
markus-spiske-hvsr_cvecvi-unsplash

Genentech and NVIDIA enter AI research collaboration

November 22, 2023
Research and Development AI, Genentech, Pharmacy, research collaboration

Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA that is intended to pair …

News

Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment

October 10, 2023
Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion

Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …

News
lungs

Genentech shares phase 3 results for ALK-positive early-stage lung cancer treatment

September 1, 2023
Research and Development Genentech, NSCLC, Oncology, clinical trials, lung cancer

Roche’s Genentech has announced that the phase 3 ALINA trial assessing Alecensa, compared with platinum-based chemotherapy for the treatment of …

News
needle-1291170_960_720

Genentech shares results from phase 3 trial for MS treatment

July 13, 2023
Research and Development Genentech, MS, Neurology, Ocrevus, clinical trial

Genentech has announced positive results from its phase 3 OCARINA II trial which assessed Ocrevus (ocrelizumab) as a twice-a-year, ten-minute …

News

Genentech’s injectable eye medicine extends time between treatments for two conditions

February 15, 2021
Sales and Marketing Genentech

Genentech has announced detailed, positive results from four Phase III studies of its investigational bispecific antibody, faricimab, for the treatment …

News
genentech_web

Genentech announces positive top-line results for “wet” age-related macular degeneration antibody

January 25, 2021
Sales and Marketing Genentech

Genentech has announced positive top-line results from two identically designed global Phase III studies, TENAYA and LUCERNE, evaluating its investigational …

News
160607140346-genentech-lung-cancer-drug-settlement-exlarge-169

Genentech’s cancer drug gets Breakthrough Therapy Designation from FDA

January 5, 2021
Manufacturing and Production Cancer, Genentech

Genentech has announced that tiragolumab, a novel cancer immunotherapy designed to bind to T cell immunoreceptor with Ig and ITIM …

News
genentech_web

Genetech scores sixth FDA approval in lung cancer with Gavreto

September 7, 2020
Sales and Marketing Cancer, FDA, Genentech, lung cancer

Genentech’s once-daily oral therapy Gavreto (pralsetinib) has secured FDA backing in the treatment of metastatic rearranged during transfection (RET) fusion-positive …

News
fdaoutsideweb

Genentech’s Evrysdi becomes first FDA-approved oral treatment for spinal muscular atrophy

August 10, 2020
Sales and Marketing Evrysdi, FDA, Genentech, Roche, spinal muscular atrophy

Genentech’s Evrysdi (risdiplam) has secured FDA approval for the treatment of spinal muscular atrophy (SMA), making it the first oral therapy …

News
shutter

UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+

July 30, 2020
Research and Development, Sales and Marketing Genentech, Roche, UCB, partnership

UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its …

News
tecentriq

Roche’s Tecentriq fails to hit main Phase 3 goal in front-line ovarian cancer

July 13, 2020
Research and Development, Sales and Marketing Genentech, Roche, ovarian cancer, tecentriq

Roche subsidiary Genentech has revealed that its immunotherapy Tecentriq (atezolizumab), combined with Avastin (bevacizumab), paclitaxel and carboplatin, fell short of …

News

Roche’s Tecentriq improves pathological complete response in triple-negative breast cancer at Phase 3

June 19, 2020
Medical Communications, Research and Development Cancer, Genentech, Roche, breast cancer, tecentriq

 

News
aviv_regev

Genentech’s retiring R&D head to be replaced by MIT executive

May 15, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Genentech, Roche, appointment

Michael Varney, industry veteran and Head of Research & Development at Genentech, has announced he is to leave the role …

Appointment

Latest content

Gilead shares phase 3 results from HIV prevention trial

June 21, 2024

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024

Takeda shares data from phase 3 trial of CIPD treatment

June 20, 2024

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024